
Scholar Rock: Beyond SMA – Anticipated Q2 2025 Obesity Treatment Data in the Biotech Sector
Scholar Rock’s Apitegromab: A Promising Treatment for Spinal Muscular Atrophy and Obesity Scholar Rock, a clinical-stage biotech company, has recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its investigational drug, apitegromab, for the treatment of patients with Spinal Muscular Atrophy (SMA). The application includes a request for…